Changes in fecal flora were evaluated in 22 healthy volunteers administered oral vancomycin or teicoplanin in 1989-1991 in Belgium. Evaluation of 5 colonies per subject revealed no glycopeptideresistant enterococci in the predominant flora before glycopeptide administration; however, large numbers (mostly Enterococcusfaecium) emerged by the end of the study in 14 (64%) of the subjects. Pediococci and lactobacilli also increased in number. In 1992, 40 healthy volunteers and 33 cancer patients were evaluated by plating stool samples directly onto selective media containing vancomycin; low numbers of vancomycin-resistant enterococci «50 cfulg) were found in 11 (28%) of the 40 and 4 (12%) of the 33 samples, respectively. DNA restriction fragment length polymorphism analysis showed that most isolates were different, but all contained vanA in Tn1546-like elements. These results indicate that vanA and Tn1546-like elements were common in Belgium as early as 1989 and that community-based individuals in that location likely form a major reservoir for glycopeptideresistant enterococci.
Enterococci are increasingly resistant to a number of antimicrobial agents, including ampicillin, due to either ,B-lactamase production or altered cell wall synthesis enzymes and high levels of aminoglycosides [1] . The first reported outbreak of infections caused by glycopeptide-resistant Enterococcus faecium and Enterococcus faecalis was in patients in England with end-stage renal failure or multiple organ failure. The outbreak occurred 3 months after institution of a regimen that included vancomycin as empiric treatment of acute undiagnosed sepsis [2] . In addition, glycopeptide-resistant enterococci were isolated from the stools of neutropenic patients in France receiving oral decontamination regimens with or without vancomycin [3, 4] .
Most subsequent reports of glycopeptide-resistant enterococci in the United States have suggested nosocomial transmission, and oral or parenteral administration of vancomycin has been cited as a common risk factor for nosocomial acquisition of vancomycin-resistant enterococci (VRE) [5] [6] [7] . However, there have been reports from Europe of VRE in sewage, in animal sources, and in stools of 3 (1.6%) of 184 general practice patients who had not been hospitalized recently [8] [9] [10] [11] . The European glycopeptide-resistant enterococci contained vanA [11] , the gene in the well-studied transposon that contains the vanA gene cluster [12] .
Oral vancomycin has been widely used as a nonabsorbable antimicrobial agent for the treatment of Clostridium difJicile and in regimens attempting oral d~contamination of the intestinal tract and prevention of bacterial infections in neutropenic patients. For the latter purpose, vancomycin has usually been combined with other nonabsorbable agents, such as colistin and nystatin, or with absorbable agents, such as fluoroquinolones. The rationale for the use of oral vancomycin in these regimens has been to eradicate the gut reservoir of staphylococci, which can play a major etiologic role in bacteremia; however, the role of the gut reservoir in these infections remains controversial. The efficacy of oral vancomycin on decreasing staphylococcal infections has not been documented adequately, and its influence on the gut flora has not been studied in detail. Teicoplanin, a glycopeptide with activity similar to vancomycin, has not been tested extensively for use in eradicating staphylococci in the gut.
The purpose of this study was to document the influence of oral teicoplanin (100 and 200 mg twice daily) and vancomycin (125 mg four times daily) for 3 weeks on the fecal flora of healthy volunteers. We were particularly interested in the possible selection of bacteria resistant to glycopeptides. We also lID 1996; 173 (May) investigated whether E. faecium containing elements related to the well-studied transposon Tn1546, which contains the vanA gene cluster, could be found as part of the normal gastrointestinal flora of humans, including persons not associated with a health care setting.
Materials and Methods
Volunteers. Twenty-two healthy volunteers participated in the studies of oral glycopeptide administration: 10 (5 males, 5 females) in a 1989 low-dose study of teicoplanin, 6 (5 females, 1 male) in a 1990 study of vancomycin, and 6 (2 females, 4 males) in a 1991 study of high-dose teicoplanin. The mean age of the volunteers was 33 years (range, 18-47), and their mean weight was 63 kg (range, 44-95). Twelve of the volunteers were involved in patient care or were hospital laboratory workers; none, to their knowledge, had been administered glycopeptides within the previous 10 years.
Oral glycopeptides. Glycopeptides were administered for 21 days. Teicoplanin was given in 100-mg capsules, with subjects receiving a low dose (one capsule twice daily) or a high dose (two capsules twice daily). Vancomycin (one 125-mg capsule) was given four times daily.
Specimens. Pharyngeal and rectal swabs, fecal and 24-h urine specimens, and 10 mL of blood were obtained before oral glycopeptide administration, on days 1, 4, 8, 11, 15, 18 of treatment, and 1 week after completion of therapy (day 28).
Assessment oforal andfecal flora. To assess fecal flora during glycopeptide administration, ' ""-' 2 g of feces was weighed and suspended in distilled water (final volume, 10 mL). Glass beads were added to help dispersion, and the mixture was vortexed for 1 min. Seven sequential 10-fold dilutions were made in distilled water, and, to distinguish and count the types of bacteria and yeasts, 10 J,LL of each dilution was plated on the following agar plates: ANC Columbia blood agar (bioMerieux, Marcy-l'Etoile, France), which contains colistin and nalidixic acid, for streptococci, enterococci, pediococci, and leuconostocs; mannitol-salt agar (biuMerieux) for staphylococci; lactobacilli MRS agar (Distri-Media, Brussels) for lactobacilli; MacConkey agar (biolvlerieux) for gram-negative bacilli; Sabouraud glucose-chloramphenicol agar (biolvlerieux) for yeast; Columbia blood agar (biolvlerieux) for the total aerobe count; Shaedler-blood agar and Shaedler-kanamycin-vancomycin agar (Becton Dickinson, Brussels) for the total anaerobe count; and CCFA (Becton Dickinson), which contains cefoxitin, cycloserine, and fructose agar, for C. difficile.
When present, at least 5 different colony types grown on ANC Columbia blood agar and mannitol-salt agar were isolated for susceptibility testing and identification. The number of colony-forming units per gram ofVRE was estimated from the number ofVRE identified from the 5 colonies tested from the greatest dilution.
Rectal and pharyngeal swabs were inoculated into tryptic soy broth (biolvlerieux), incubated for 24 h, and then inoculated onto the agar media.
Identification and drug susceptibility tests. The species of each colony type of streptococci, enterococci, and staphylococci was identified using API-Strep ID32 or API-Staph ID32 (API, Marcy-1'Etoile, France). Strains of enterococci were screened for highlevel resistance to gentamicin by use of disks containing 200 J,Lg of gentamicin (Rosco-Diagnostica, Taastrup, Denmark). MICs of teicoplanin and vancomycin were measured by broth microdilution according to guidelines of the National Committee for Clinical Laboratory Standards [13] . Most strains with elevated MICs (> 1 mg/L) were also tested by the agar dilution method [13] . During the high-dose teicoplanin study, rapid screening of glycopeptide resistance was done using the E-test (Epsilometer) antibiotic strips (AB Biodisk, Solna, Sweden); resistant strains were confirmed by agar dilution and broth microdilution tests. Many of the glycopeptide-resistant strains were stored at -80°C for subsequent studies.
Antibiotic concentrations. The concentration of teicoplanin was measured in each stool specimen by use of a fluorescence polarization immunoassay (FPIA; Biomedical Diagnostic, Brussels, Belgium). About 0.1 g of feces was weighed and added to 0.5 mL of FPIA buffer. After being sonicated for 1 min at low power, the samples were centrifuged, and the supernatant was tested. Results were expressed as milligrams per kilogram of feces. Vancomycin concentrations were measured in the same manner, using vancomycin reagents (Abbott, Louvain-la-Neuve, Belgium). FPIAs were run on the TDX machine (Abbott). The sensitivity of the FPIA in stool specimens was 10 mg/kg. Serum and urine specimens were tested as well (detection limit ofthe two glycopep-
Determination offecal carriage ofhighly glycopeptide-resistant enterococci. To document carriage of glycopeptide-resistant enterococci, we initiated a subsequent study using stool specimens obtained from 40 healthy persons who were not health care workers and from 33 cancer patients hospitalized at Institut Jules Bordet. The healthy subjects, who were living in Charleroi, Belgium, in 1992, had not received any antimicrobial agents for the previous year and had never knowingly been exposed to a glycopeptide. Their fecal samples were plated on ANC Columbia blood agar with either gentamicin (1000 mg/L) or vancomycin (16 mg/L). The plates were incubated for 48 h at 37°C, and colonies suspected of being enterococci were further isolated for susceptibility testing and identification as described above. The same procedure was used with fecal samples obtained from the hospitalized patients, who previously had received various antimicrobial agents, including intravenously administered,vancomycin.
Analysis ofstrains by pulsed-jield gel electrophoresis (PFGE).
Genomic DNA was prepared in agarose plugs as previously described [14] . Slices of agarose containing DNA were incubated overnight at 25°C with SmaI (New England Biolabs, Beverly, MA). The agarose slice was then placed in the wells of 1.2% Seaplaque GTG agarose gels (FMC BioProducts, Rockland, ME) in 0.5X TBE buffer (1X TBE is 0.089 M TRIS-HCl, 0.089 M boric acid, and 0.025 M EDTA). Electrophoresis was done using a contourclamped homogeneous electric field gel electrophoresis apparatus (CHEF-DRII; Bio-Rad, Richmond, CA). Patterns were considered related, suggesting a common origin of the isolates, if their banding patterns were identical or differed by one to three bands. Some isolates were also analyzed with ApaI (New England Biolabs).
Hybridization and polymerase chain reaction (PCR). Available isolates that had MICs of vancomycin and teicoplanin >64 mg/L were considered to be highly resistant to the glycopeptides (VanA phenotype) and were probed, as described elsewhere [12] , for the presence of vanA. Strains ofEnterococcus gallinarum were probed for the presence of vanC-l [15] .
To test for the presence of Tn1546-related sequences, we prepared enterococcal DNA as described above [14] and di- figure 1 , were used as probes in hybridization experiments, as previously described [12] . The probes were labeled by the random-priming method with an oligonucleotide kit (Pharmacia, Piscataway, NJ) using [a-32 P]dCTP (3000 CI/mmol; ICN Biomedicals, Costa Mesa, CA). Hybridization was done overnight using stringent conditions (60°C in 0.1% SDS, 0.7% nonfat dry milk, 6x SSC [IX SSC is 0.15 MNaCI and 0.015 M sodium citrate, pH 7.0]) [12] . Washes were done at 60°C in 2X SSC and 0.1% SDS. For PCR analysis, six pairs of oligonucleotides were used to amplify overlapping fragments internal to Tn1546, as shown in figure 1 and as described by Arthur et al. [12] .
E. faecium BM4147 harboring Tn1546 on the plasmid plP816 and E. faecium BM4147-1 (a derivative of BM4147 susceptible to glycopeptides, obtained by plasmid curing) were used as positive and negative controls, respectively [12] .
Results
Antibiotic concentrations. Neither vancomycin nor teicoplanin (both dosages) was detectable in serum or urine samples « I mg/L). Concentrations of both orally administered glycopeptides were very high in fecal samples. The highest concentrations (> 1800 mg/kg) were achieved after 10-15 days of treatment. Fecal concentrations of teicoplanin were similar in high-and low-dose subjects.
Assessment of oral and fecal flora.
Results of rectal swab cultures were similar to those of fecal cultures; however, quantitation was more reproducible in fecal samples. Therefore, results are presented only for fecal cultures. In general, the most striking result was the isolation, following glycopeptide administration, of enterococci (mostly E. faecium) that were highly resistant to both glycopeptides (figure 2). The number of glycopeptide-resistant enterococci isolated depended on the drug given, with more found in the teicoplanin groups, irrespective ofthe dose administered. No glycopeptide-resistant E.faecium were detected in stool specimens obtained before study entry; however, low numbers of resistant organisms would have been missed, since stool specimens were not inoculated directly onto vancomycin-containing agar. C. difJicile was never isolated from the 22 volunteers, and no significant changes were detected in the oral flora of the subjects.
Low-dose teicoplanin. Figure 3 shows the evolution of viable counts of aerobically grown gram-positive bacteria in the stools of volunteers receiving 100 mg of oral teicoplanin twice daily. Highly glycopeptide-resistant Pediococcus species were isolated from the stools of all volunteers; most were Pediococcus acidilactici. Leuconostoc species were not isolated. No VRE were identified before drug exposure, but highly glycopeptide-resistant enterococci were isolated in 8 of 10 volunteers who received low-dose oral teicoplanin, with some volunteers having up to 10 6 -10 8 cfu of VREIg of stool. mg bid)   100+--.....-......-....-.--.....-......-......-...._ ......_ ......_ Most of the highly glycopeptide-resistant enterococci were E. faecium (table 1) , with the exception of isolates from 1 volunteer with E. faecalis (not shown in table 1 because the strain was not available for further characterization) and 1 with Enterococcus durans. E. faecium isolates from 2 volunteers hybridized to the probe for vanA (table 1) . VRE were still isolated 1 week after the last dose, although 78% of the isolates on ANC Columbia agar at that time were again susceptible to glycopeptides.
Coagulase-negative staphylococci were isolated in low numbers from subjects before study entry (~10 4 cfu/g), and numbers remained low throughout the study. No teicoplanin-resistant isolates (MIC >8 mg/L) were recovered while subjects received treatment; however, the proportion of recovered strains with low-level resistance (MICs = 4-8 mg/L) increased significantly (from 0% to 80%) during teicoplanin treatment (analysis of variance for repeated measures, P <.05). The number of lactobacilli increased significantly during teicoplanin administration. The number of yeast remained low, and the number of gram-negative bacilli and total aerobes increased to 10 9 cfulg. High-dose teicoplanin. In the 3 weeks during which subjects received 200 mg of teicoplanin twice daily, bacterial growth on ANC Columbia blood agar decreased dramatically during the first 5 days, followed by a slow increase in growth (data not shown). The increase was associated with the growth of highly glycopeptide-resistant Pediococcus species and enterococci. Vancomycin-and teicoplanin-resistant E. faecium that hybridized to a probe for vanA were isolated from 5 of 6 volunteers; 1 of these subjects also was colonized by a highly resistant E. durans (table 1) . In addition, enterococci were isolated from 2 volunteers who had low-level resistance to vancomycin and were susceptible to teicoplanin. E. gallinarum with MICs of vancomycin (8-16 mg/L) and teicoplanin (1 mg/ L) was isolated from volunteer TH-1 after 21 days of treatment with teicoplanin. Enterococcus hirae with MICs ofvancomycin (2-8 mg/L) and teicoplanin (0.5 mg/L) was recovered from volunteer TH-2 at day 0 of drug administration, and isolates with MICs of 8-16 mg/L (vancomycin) and 1 mg/L (teicoplanin) were recovered at day 28.
After treatment, the number of staphylococci decreased to an undetectable level « 10 cfu/g). Lactobacilli numbers increased rapidly to 10 8-109 cfu/g within 5 days. The number of yeast remained low, but the number of gram-negative bacilli and total aerobes increased to 10 9 cfulg. Vancomycin. In volunteers receiving oral vancomycin, bacterial growth on ANC Columbia agar decreased slowly up to day 15 of treatment, after which increased numbers of organisms were observed (data not shown). This was associated with the emergence of Pediococcus species in all 6 volunteers; vancomycin-resistantE.faecium were recoveredfrom 1. Numbers of staphylococci slowly decreased but recovered after vancomycin was stopped. As in the low-and high-dose teicoplanin studies, the number of lactobacilli increased dramatically (up to 10 7 cfu/g) during vancomycintreatment. Other categoriesof microorganisms were not significantlyaffected, although some increases in gramnegative bacilli and total aerobes were observed.
Fecal carriage of highly glycopeptide-resistant enterococci in healthy subjects and hospitalized patients. Using a method in which stool specimens were plated directly onto vancomycin-containing agar, we found that 11 (28%) of 40 healthy subjects never exposed to a glycopeptide had low numbers «50 cfu/g) of glycopeptide-resistant E.faecium in their stools. Among the 33 cancer patients who had been exposed to a glycopeptide within the 6 months prior to testing, 4 (12.1%) had low amounts «50 cfu/g) of vancomycin-resistant enterococci in their stools.
{3-lactamase production and high-level resistance to gentamicin. None of the enterococci tested were positive by the chromogenic cephalosporin nitrocefin test using a heavy inoculum. None of the glycopeptide-resistant strains were highly resistant to gentamicin, and no enterococci were recovered from the gentamicin-containing media from fecal specimens of healthy controls or hospitalized patients.
Typing of the glycopeptide-resistant enterococci by PFGE. Overall, a wide variety of different strains, as defined by very different PFGE patterns, was found among the vancomycinresistant E. faecium (table 1) . The restriction patterns of glycopeptide-susceptible strains that were available for testing were always different from those of resistant strains, including those of strains from 4 subjects who had both vancomycin-resistant and vancomycin-susceptible E. faecium isolated from their stools (data not shown). As shown in table 1, some of the volunteers harbored > 1 resistant E. faecium strain. Occasionally, strains that were closely related or identical by PFGE patterns were found in different volunteers. This was observed for PFGE pattern Al in volunteers 1, 3, and 6, who were receiving high doses of teicoplanin. In the healthy carriage group, an identical strain (pattern A26) was noted for subjects 33 and 34, and another strain (pattern A25) was found in subjects 27, 32, and 37. Patterns A14 and A21 were somewhat similar with SmaI but clearly different using ApaI; thus, they were assigned different pattern numbers.
Presence of the vanA gene and Tn1546-related sequences. Although not all vancomycin-resistant enterococci were saved for further study, 35 isolates with high-level resistance to vancomycin (> 128 mg/L) and to teicoplanin (>32 mg/L) were evaluated by DNA:DNA hybridization, including 2 E. durans, 31 E. faecium, and 2 E. faecalis strains. All hybridized with the DNA probe for vanA (table 1). Using the 6 pairs of oligonucleotides internal to Tn1546, we obtained from all 35 strains studied the PCR products that comigrated with the amplification products obtained from E. faecium BM4147 (data not shown). Restriction digestion products of total DNA from 31 strains were also analyzed by hybridization to probes A and C (figure 1). With BM4147, which contains Tn1546, a 6.3 kb BgnI fragment internal to the transposon was visualized after hybridization either to probe A or C; similarly, internal 3.1-kb HindIII-EcoRi and 4.0-kb EcoRI~HindIII fragments were detected after hybridization to probes A and C, respectively. On the basis of the comigration of bands resolved in adjacent lanes of agarose gels and hybridization, internal HindIII, EcoRI, and BgnI fragments of Tn1546 were present in most strains, including E. faecalis and E. durans (table 1). For 1 strain (from volunteer TH-2, no. 7), the internal 4.0-kb fragment was replaced by a 3.9-kb fragment.
Junction fragments ofTn1546-like elements. With plasmid pIP816, the BgnI junction fragments of Tn1546 (delineated by one Bglt) restriction site within the transposon and one site in the surrounding genetic region) of 6.4 kb and 11.5 kb were demonstrated after hybridization with probes A and C, respectively. For 20 strains, Bglil. fragments comigrated with the BgnI fragments from BM4147 (pIP816). The genomic environment was different for 11 other strains, since junction fragments of different sizes were seen after hybridization with probes A or C or both.
Discussion
This study documented that oral administration of glycopeptides, particularly teicoplanin, was associated with a rapid shift of the predominant gram-positive fecal flora from glycopeptide-susceptible to glycopeptide-resistant; both naturally resistant species, such as Pediococcus, and species of enterococci with acquired resistance were found. The risk of selecting highly vancomycin-and teicoplanin-resistant enterococci was lower with vancomycin (1/6 volunteers) than with teicoplanin (13/16 volunteers) . This was observed despite extremely high fecal concentrations of both glycopeptides. Detection of these organisms by the method of picking single colonies from nonglycopeptide-containing CNA plates indicates that they were part of the predominant flora isolated on this medium, with estimated counts reaching 10 6 -10 8 cfu/g. The isolation of moderately resistant coagulase-negative staphylococci (mostly Staphylococcus epidermidis) during the low-dose (100 mg twice daily) teicoplanin study suggests that teicoplanin bioactivity is low in stools, with free drug lower than the MICs for the persisting staphylococci « 10-20 mg/ L). The dilution step for the FPIA might allow elution of the less tightly bound teicoplanin from the fecal matrix. Bioactivity of vancomycin appeared to be higher, since staphylococci remained suppressed, indicating high levels of free drug. It is not known if this explains the lower recovery of VRE from the vancomycin group or whether this group lacked colonization, exposure, or both to VRE.
The rapid emergence of glycopeptide-resistant enterococci in some subjects receiving oral glycopeptides strongly suggested that these organisms were present before exposure to antibiotics or, alternatively, that acquisition of vancomycin resistance from an unrecognized reservoir (e.g., an unknown microorganism in the feces) had occurred. Unfortunately, stool specimens in the glycopeptide study groups were not plated directly onto vancomycin-containing agar; thus, low numbers ofVRE would have been missed. Moreover, some of the volunteers worked in health care facilities and might have been exposed to hospital-associated organisms.
The possibility that VRE may be present in the normal human gastrointestinal tract was corroborated by the finding of glycopeptide-resistant E. faecium in stools (detected by plating directly onto vancomycin-containing agar) of 11 (28%) of the 40 healthy community-based volunteers who were not health care workers, had not received any antibiotic for at least 1 year, and had never, to their knowledge, received glycopeptides. Molecular typing ofthe highly vancomycin-resistant E. faecium showed great heterogeneity among the strains; indeed, some volunteers were simultaneously colonized by different strains of vancomycin-resistant E. faecium. It was also clear that on occasion, a strain was present in > 1 subject, suggesting the possibility of a common source for some organisms.
All of the vancomycin-resistant E. faecium and E. faecalis isolates tested displayed combined high-level vancomycin and teicoplanin resistance (i.e., the VanA phenotype) and hybridized with the probe for vanA. In addition, these strains contained DNA regions similar to Tn1546, the transposon previously reported to contain the vanA gene cluster [12] , including strains from the hospitalized patients and the healthy volunteers not associated with medical care. This indicates that Tn1546-like elements are responsible, at least in part, for spread ofVanA-type vancomycin resistance in the community as well as in the hospital setting. Because of these results, the possible presence ofvanB was not explored; thus, the existence of vanA and vanB in these strains cannot be excluded.
The source of the glycopeptide-resistant enterococci found in the gastrointestinal flora of subjects in this study is not known. The recovery of vancomycin-and teicoplanin-resistant E. faecium from chicken carcasses in England [8] and Germany [11] together with the use for > 15 years of the glycopeptide avoparcin for growth promotion in animal feeds in Europe [16] suggest that vancomycin-resistant E. faecium could have emerged first in feed animals and then spread through the food chain. The common use of orally administered E. faecium as a probiotic for humans and animals [11, 17, 18] and the occasional use of E. faecium for cheese fermentation in some locations suggest another possible mode of entry into humans: A vancomycin-resistant strain could inadvertently be introduced into these preparations. It would be of interest to conduct studies similar to the current one in areas of the world where vancomycin-resistant E. faecium have not yet been described and where glycopeptides are not used in animal feeds.
In conclusion, we have shown that highly glycopeptide-resistant enterococci can be selected by oral glycopeptides and can reach high numbers (up to 10 6-108 cfu/g) in feces. These organisms were also found in low numbers in stool specimens of healthy, community-based subjects who were not health care workers and who were not, to their knowledge, previously exposed to glycopeptides. These strains were not simultaneously resistant to gentamicin, and none expressed ,B-lactamase. The presence of vanA and Tn1546-related sequences was demonstrated in 3 species of enterococci: E. faecalis, E. faecium, and E. durans. These results provide further evidence that stools from healthy persons in Europe can be a natural reservoir for VanA-type glycopeptide resistance. Whether these organisms are present in humans worldwide or were present in this population because of exposure to food, water, or other environmental sources is unknown. As a practical consequence, the use of oral glycopeptides should be strongly discouraged to prevent selection for high numbers of glycopeptide-resistant organisms, since greater numbers of these strains would increase the chances of spreading these resistant organisms to other persons and increase the opportunities for spread of the resistance genes to other organisms. Gervasi, D. Marsales and A. Beck for valuable assistance with manuscript preparation.
